CLVLF Stock UPDATES Clinuvel Pharm Ords (CLVLF) 2.8500 09/11/2014
Post# of 273254
Posted On: 09/11/2014 9:13:44 AM
Clinuvel Pharm Ords (CLVLF) 2.8500 $CLVLF
Retrophin plans to buy remaining shares in Clinuvel Pharmaceuticals in all cash offer
M2 - Mon Jul 28, 6:13AM CDT
Pharmaceutical company Retrophin (NasdaqGM:RTRX) on Sunday announced its proposal to acquire all of the remaining shares of Clinuvel Pharmaceuticals (ASX:CUV.AX).
Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals
Business Wire - Sun Jul 27, 10:47PM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced that on July 17, 2014 it submitted a proposal to the Board of Directors of Clinuvel Pharmaceuticals Ltd (ASX:CUV) to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for (1) 0.175 Retrophin shares per Clinuvel share, or (2) A$2.17 per share in cash. Retrophin currently owns approximately 4.88% of Clinuvel shares.
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
Vitiligo - Pipeline Review, H1 2013
M2 - Mon Jun 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6wkh6/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2013" report to their offering. "Vitiligo - Pipeline Review, H2 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Vitiligo, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vitiligo. Scope - A snapshot of the global therapeutic scenario for Vitiligo. - A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Vitiligo pipeline on th
SurModics Signs License Agreement with Clinuvel Pharmaceuticals
M2 - Sun Jun 16, 7:09AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.
Retrophin plans to buy remaining shares in Clinuvel Pharmaceuticals in all cash offer
M2 - Mon Jul 28, 6:13AM CDT
Pharmaceutical company Retrophin (NasdaqGM:RTRX) on Sunday announced its proposal to acquire all of the remaining shares of Clinuvel Pharmaceuticals (ASX:CUV.AX).
Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals
Business Wire - Sun Jul 27, 10:47PM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced that on July 17, 2014 it submitted a proposal to the Board of Directors of Clinuvel Pharmaceuticals Ltd (ASX:CUV) to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for (1) 0.175 Retrophin shares per Clinuvel share, or (2) A$2.17 per share in cash. Retrophin currently owns approximately 4.88% of Clinuvel shares.
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
Vitiligo - Pipeline Review, H1 2013
M2 - Mon Jun 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6wkh6/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2013" report to their offering. "Vitiligo - Pipeline Review, H2 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Vitiligo, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vitiligo. Scope - A snapshot of the global therapeutic scenario for Vitiligo. - A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Vitiligo pipeline on th
SurModics Signs License Agreement with Clinuvel Pharmaceuticals
M2 - Sun Jun 16, 7:09AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.
(0)
(0)Scroll down for more posts ▼